ClinicalTrials.gg
Active, not recruitingNCT00761618Updated Oct 13, 2026

Intrapleural Catheter Daily Versus Three Times a Week Drainage

A Phase 2 interventional study of Intrapleural catheter (IPC) drained and IPC Placement in Advanced Cancer and Pleural Effusion, sponsored by M.D. Anderson Cancer Center. Active, not recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-13.

Sponsored by M.D. Anderson Cancer Center · Phase 2, Interventional, and Treatment

How we know

Updated Oct 13, 2026Primary completion movedStudy completion movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
257
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 45 studies in Pleural Effusion with a site in United States — 6 open to participants now, 9 under way, none of them phase 3. Pleural Effusion · United States.

Enrollment
4th of 34
257 · median 42
Started
2008
with 1 other
Phase 2
7 of 45
1 open now
Registered
8th of 45
by date
Lead sponsor
3 of 45
M.D. Anderson Cancer Center

Among the 45 studies in Pleural Effusion with a site in United States, this one is the 4th largest by enrollment of the 34 interventional ones that give a count, is one of 2 that started in 2008, is one of 7 in phase 2, and was the 8th registered.

Pleural Effusion

241 studies on the registry are indexed under Pleural Effusion; 49 are open to participants now.

Browse Pleural Effusion studies →

Open to participants now

6 of the 45 studies in Pleural Effusion with a site in United States are open now. Recruiting first, the newest first:

1 more — sign in →

All 6 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 30 Pleural Effusion studies recruiting now, 25 (83%) set no upper age limit and 2 (7%) stop at 75 or younger; 3 take children under 18; 3 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 45 studies in Pleural Effusion with a site in United States, or all of them as a file.
02

Study summary

The goal of this clinical research study is to learn if draining the IPC every day is better at than draining it 3 times a week.

Read the detailed description

An IPC is a silicone (rubberlike) tube that is inserted into the chest cavity to drain excess fluid that is in your chest. At MD Anderson, patients are told to drain their IPC every day. At other institutions, patients are told to drain their IPC less often.

Before IPC Placement:

Before you can have the IPC inserted, the following tests and procedures will be performed to help the doctor decide if you need to have an IPC inserted:

  • You will perform a 6 minute walk test to learn your check your breathing ability and fatigue level. To perform the walk test, you will be asked to walk as far as possible around cones on a flat indoor course that is about 40 yards long. You will walk at your own pace and can take breaks at any time if necessary.
  • After signing this consent, you will fill out 2 questionnaires asking questions about how you feel and any symptoms you may have. These questionnaires will take about 20-30 minutes to complete.

IPC placement:

You will have an IPC placed to drain the fluid in your chest cavity. You will be given a separate consent for to sign for this procedure and your doctor will give you detailed instructions regarding the procedure itself.

Study Groups:

A chest x-ray will be performed right after the IPC placement. You will be randomly assigned (as in the flip of a coin) to 1 of 2 groups, after your chest x-ray or the following day when you return to clinic for follow up. Group 1 will have their IPC drained every day, and Group 2 will have their IPC drained 3 times a week (Monday, Wednesday, and Friday or Tuesday, Thursday, and Saturday). You will be given detailed instructions on when and how to drain your catheter.

Follow-Up Visits:

Two (2) weeks after you receive the IPC, you will return to the clinic for a follow-up visit so the doctor can check your IPC for possible leaking, infection, and see how much pleural fluid has drained. After the follow-up visit at 2 weeks, you will come into the clinic every 4 weeks until your IPC is removed. During each follow-up visit the following tests and procedures will be performed to see how your condition has changed:

  • You will have a chest x-ray to see if the amount of pleural fluid has decreased and to see if your lung has re-expanded.
  • You will perform the 6 minute walk test.
  • You will complete the same 2 questionnaires.
  • The IPC will be drained.

After the IPC is removed, at 3 and 6 months, you will have follow-up visits at M. D. Anderson or at your local doctor's office. At these visits you will have chest x-rays to see if the pleural fluid has come back or not.

The study personnel will contact you by phone, email or mail periodically during the study and at 3 months and 6 months after the IPC has been removed to check on your status. The phone calls, email, or mail follow-up will take about 5-10 minutes to complete. You will be asked how you are doing and if you have any questions or concerns that you may want to discuss with the your doctor. You will also be asked if you have had a chest x-ray since being off study. If you have had an x-ray, you will be asked to share the results with the study doctor.

This is an investigational study.

Up to 250 patients will take part in this study. All will be enrolled at MD Anderson.

03

Conditions studied

  • Advanced Cancer
  • Pleural Effusion

Keywords

  • Intrapleural catheter
  • IPC
  • Pleurodesis
  • PD
  • Pleural effusion
  • Fluid in the chest cavity
  • Recurrent malignant pleural effusion
  • MPE
  • Pleural inflammatory response
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Patients with symptomatic pleural effusion requiring placement of an IPC.
  2. Signed prior to any study related procedures.
  3. Subject must be age 18 years or over.

Exclusion criteria

Exclusion Criteria:

  1. Any of the following interventions on the affected hemithorax: prior IPC, prior chest tube placement, history of chemical or mechanical pleurodesis, history of thoracotomy within 4 weeks incompletely healed surgical incision before randomization.
  2. Evidence of empyema or history of empyema of the affected hemithorax
  3. Non-correctable bleeding diathesis
  4. Any psychological, familial, sociological or geographical condition potentially hampering compliance with the study protocol and follow-up schedule.
  5. Evidence of severe or uncontrolled systemic disease or any concurrent condition which in the Principal Investigator's opinion makes it undesirable for the patient to participate in the trial or which would jeopardize compliance with the protocol.
  6. Participation in any clinical trial that prevents randomization of the subject to either strategy.
  7. Clinical evidence of skin infection at the potential site of IPC placement.
  8. Current or prior IPC placement, or any intervention to manage recurrent malignant pleural effusion on the contralateral hemithorax (excluding thoracentesis).
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
257 participants (actual)

Study arms

  • Experimental
    Arm 1 - Daily

    Intrapleural Catheters (IPC) drained every day

    Procedure: Intrapleural catheter (IPC) drained · Procedure: IPC Placement · Radiation: Chest X-Ray

  • Experimental
    Arm 2 - 3 Times a Week

    IPC drained 3 times a week

    Procedure: Intrapleural catheter (IPC) drained · Procedure: IPC Placement · Radiation: Chest X-Ray

Interventions

  • ProcedureIntrapleural catheter (IPC) drained

    IPC drained daily (Group 1) or 3 times per week (Group 2)

  • ProcedureIPC Placement

    IPC placed in chest cavity to drain excess fluid

    Also known as: Indwelling Pleural Catheter

  • RadiationChest X-Ray

    Chest X-Rays at 3 and 6 month follow up visits

06

What researchers measure

Primary outcomes

  1. Time to Pleurodesis (TTP)

    Time to pleurodesis (TTP), defined as the time from catheter insertion to catheter removal.

    Time frame: 2 weeks after intrapleural catheter placement

07

Study locations

1 site
08

References and documents

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Started Aug 2008 (actual). Primary completion is estimated for Aug 2028, 240 months after the start.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 13, 2026: primary completion Aug 2026 → Aug 2028 and completion Aug 2026 → Aug 2028.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Sep 25, 2008
First posted
Sep 29, 2008
StartActual
Aug 22, 2008
Primary completionEst.
Aug 31, 2028was Aug 2026
CompletionEst.
Aug 31, 2028was Aug 2026
Last update
Oct 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
Aug 31, 2026→Aug 31, 2028
Oct 13, 2026
Study completion
Aug 31, 2026→Aug 31, 2028
Oct 13, 2026
Show all 1 update
  1. Oct 13, 2026
    Primary completion Aug 31, 2026→Aug 31, 2028
    Study completion Aug 31, 2026→Aug 31, 2028
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT00761618
Collaborators
C. R. Bard
Responsible party
Sponsor
First posted
Sep 29, 2008
Start date
Aug 22, 2008
Primary completion
Aug 31, 2028 (estimated)
Completion
Aug 31, 2028 (estimated)
Last update
Oct 13, 2026

Study contacts

Carlos A. Jimenez, MD
principal investigator · M.D. Anderson Cancer Center

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion